Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
CD8 positive
i
Other names:
CD8, CD8A, cluster of differentiation 8, CD8a Molecule, T-Cell Surface Glycoprotein CD8 Alpha Chain, T-Lymphocyte Differentiation Antigen T8/Leu-2, CD8 Antigen, Alpha Polypeptide (P32), Leu2 T-Lymphocyte Antigen, OKT8 T-Cell Antigen, T-Cell Antigen Leu2, T Cell Co-Receptor, T8 T-Cell Antigen, CD8a Antigen
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
925
Related biomarkers:
Expression
Others
‹
›
Related tests:
Immunoscore®
Immunoscore®
Associations
(7)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia (NCI-2019-08626) (NCT04214249)
Phase 2
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Recruiting
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
06/05/2024
Initiation :
02/17/2021
Primary completion :
07/31/2024
Completion :
07/31/2024
PD-L1 • TMB • CD8 • PD-1 • CD47 • GZMB • FOXP3
|
PD-L1 expression • PD-1 expression • CD8 positive • CD47 expression
|
Keytruda (pembrolizumab) • cytarabine • daunorubicin • idarubicin hydrochloride • Starasid (cytarabine ocfosfate)
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma (NCT04093323)
Phase 2
Roswell Park Cancer Institute
Roswell Park Cancer Institute
Recruiting
Phase 2
Roswell Park Cancer Institute
Recruiting
Last update posted :
05/30/2024
Initiation :
06/20/2024
Primary completion :
08/22/2025
Completion :
08/22/2025
CD8
|
CD8 positive
|
Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib (NCT04614194)
Phase 2
University of Texas Southwestern Medical Center
University of Texas Southwestern Medica...
Recruiting
Phase 2
University of Texas Southwestern Medical Center
Recruiting
Last update posted :
05/20/2024
Initiation :
04/15/2021
Primary completion :
04/15/2026
Completion :
04/15/2028
HER-2 • ER • PGR • CD8
|
HER-2 negative • ER positive + PGR positive • PGR positive • CD8 positive
|
Verzenio (abemaciclib) • letrozole
PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (CheckMate-038) (NCT01621490)
Phase 1
Bristol-Myers Squibb
Bristol-Myers Squibb
Completed
Phase 1
Bristol-Myers Squibb
Completed
Last update posted :
04/23/2024
Initiation :
09/27/2012
Primary completion :
09/12/2017
Completion :
10/25/2018
CD8 • IFNG • CXCL10 • CXCL9 • CD4
|
CD8 positive • CD4 positive
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
A Study of Ruxolitinib and Duvelisib in People With Lymphoma (NCT05010005)
Phase 1
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Phase 1
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
04/04/2024
Initiation :
08/12/2021
Primary completion :
08/01/2025
Completion :
08/01/2025
CD8
|
CD8 positive
|
Jakafi (ruxolitinib) • Copiktra (duvelisib)
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer (NCT04080804)
Phase 2
Robert L. Ferris, MD, PhD
Robert L. Ferris, MD, PhD
Recruiting
Phase 2
Robert L. Ferris, MD, PhD
Recruiting
Last update posted :
01/11/2024
Initiation :
01/08/2020
Primary completion :
05/31/2027
Completion :
09/30/2027
TMB • LAG3
|
CD8 positive
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)
CVD 37000: Immunity and Microbiome Studies at Intestinal and Systemic Sites in Ty21a Vaccinated Adults (NCT03970304)
Phase 4
University of Maryland, Baltimore
University of Maryland, Baltimore
Active, not recruiting
Phase 4
University of Maryland, Baltimore
Active, not recruiting
Last update posted :
12/07/2023
Initiation :
10/24/2013
Primary completion :
06/30/2024
Completion :
06/30/2024
CD8 • IFNG • TNFA
|
CD8 positive
Feasibility of a Health Care Provider Guided Exercise Intervention Prior to Surgical Resection of Pancreatic Cancer (NCT05483075)
Phase N/A
NYU Langone Health
NYU Langone Health
Recruiting
Phase N/A
NYU Langone Health
Recruiting
Last update posted :
11/09/2023
Initiation :
11/15/2022
Primary completion :
03/01/2024
Completion :
09/01/2024
CD8 • GZMB
|
CD8 expression • CD8 positive
VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2 (NCT03499795)
Phase 2
Inovio Pharmaceuticals
Inovio Pharmaceuticals
Completed
Phase 2
Inovio Pharmaceuticals
Completed
Last update posted :
07/14/2023
Initiation :
05/15/2018
Primary completion :
06/16/2020
Completion :
05/26/2021
CD8 • TNFRSF9
|
CD8 positive
|
bizalimogene ralaplasmid (VGX-3100)
A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) (NCT02580058)
Phase 3
Pfizer
Pfizer
Completed
Phase 3
Pfizer
Completed
Last update posted :
07/10/2023
Initiation :
12/21/2015
Primary completion :
09/19/2018
Completion :
07/12/2022
PD-L1 • CD8
|
PD-L1 expression • CD8 positive
|
Bavencio (avelumab) • pegylated liposomal doxorubicin • doxorubicin liposomal
WIRE - Novel Treatments in Renal Cell Cancer (NCT03741426)
Phase 2
CCTU- Cancer Theme
CCTU- Cancer Theme
Recruiting
Phase 2
CCTU- Cancer Theme
Recruiting
Last update posted :
06/07/2023
Initiation :
07/27/2020
Primary completion :
11/30/2025
Completion :
11/30/2025
CD8 • IL2
|
CD8 positive
|
Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)
Dendritic Cell Vaccination for Patients With Solid Tumors (NCT01291420)
Phase 1/2
University Hospital, Antwerp
University Hospital, Antwerp
Completed
Phase 1/2
University Hospital, Antwerp
Completed
Last update posted :
05/12/2023
Initiation :
05/03/2010
Primary completion :
04/25/2016
Completion :
05/05/2018
HER-2 • KRAS • PGR • CD8 • WT1
|
HER-2 negative • RAS wild-type • CD8 positive
Metformin Treatment for Colon Cancer (MECORA) (NCT03359681)
Phase 2
Zealand University Hospital
Zealand University Hospital
Completed
Phase 2
Zealand University Hospital
Completed
Last update posted :
03/03/2022
Initiation :
07/10/2018
Primary completion :
09/02/2021
Completion :
10/04/2021
CD8 • CASP3
|
CD8 positive
|
metformin
Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest. (NCT05044728)
Phase 2
Sichuan Cancer Hospital and Research Institute
Sichuan Cancer Hospital and Research In...
Recruiting
Phase 2
Sichuan Cancer Hospital and Research Institute
Recruiting
Last update posted :
09/15/2021
Initiation :
04/01/2021
Primary completion :
04/01/2022
Completion :
03/31/2023
CD8
|
CD8 positive
|
carboplatin • paclitaxel
Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT) (NCT03453164)
Phase 1/2
Fukushima Medical University
Fukushima Medical University
Unknown status
Phase 1/2
Fukushima Medical University
Unknown status
Last update posted :
07/15/2020
Initiation :
03/28/2018
Primary completion :
01/14/2021
Completion :
02/28/2021
PD-L1 • CD8
|
PD-L1 expression • CD8 positive
|
Opdivo (nivolumab)
Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer (NCT00266110)
Phase 2
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
Completed
Phase 2
UNC Lineberger Comprehensive Cancer Center
Completed
Last update posted :
09/12/2018
Initiation :
12/01/2005
Primary completion :
02/01/2013
Completion :
10/27/2017
HER-2 • CD8 • IFNG
|
HER-2 expression • CD8 positive
|
Herceptin (trastuzumab) • vinorelbine tartrate • Leukine (sargramostim)
Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity (PRIMED-001) (NCT02993991)
Phase 1
University Health Network, Toronto
University Health Network, Toronto
Withdrawn
Phase 1
University Health Network, Toronto
Withdrawn
Last update posted :
12/29/2017
Initiation :
10/10/2017
Primary completion :
12/21/2017
Completion :
12/21/2017
PD-L1 • CD8 • CD4
|
CD8 positive
|
Imfinzi (durvalumab) • mocetinostat (MGCD0103)
Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery (NCT01989559)
Phase 1
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Completed
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
01/26/2015
Initiation :
10/01/2002
Primary completion :
09/01/2013
Completion :
09/01/2013
CD8
|
CD8 positive
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login